Search results for "Hypoglycemic Agents."

showing 10 items of 211 documents

Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells

2009

Leptin is overexpressed in human breast tumors and is produced by breast cancer cells in response to obesity-related stimuli. The leptin promoter polymorphism Lep-2548G/A can be associated with increased leptin secretion by adipocytes and elevated cancer risk. However, molecular mechanisms underlying the link between Lep-2548G/A and breast cancer have never been addressed. Lep-2548G/A is proximal to a binding site for the transcriptional factor Sp1. Furthermore nucleolin, a transcriptional repressor, can bind Sp1 or its consensus site. Consequently, we focused on the impact of Lep-2548G/A on Sp1- and nucleolin-dependent leptin transcription in breast cancer cells. The Lep-2548G/A was identi…

LeptinChromatin ImmunoprecipitationCancer Researchmedicine.medical_specialtyGenotypeSp1 Transcription FactorBlotting WesterneducationAdipokineBreast NeoplasmsBiologyBody Mass IndexBreast cancerInternal medicineTumor Cells CulturedmedicineHumansHypoglycemic AgentsInsulinObesityRNA MessengerPromoter Regions Genetichealth care economics and organizationsPolymorphism GeneticLeptin receptorReverse Transcriptase Polymerase Chain ReactionLeptinRNA-Binding ProteinsCancerPhosphoproteinsmedicine.diseaseEndocrinologyOncologyCancer researchImmunohistochemistryBreast diseaseNucleolinhormones hormone substitutes and hormone antagonistsInternational Journal of Cancer
researchProduct

Insulin-dependent leptin expression in breast cancer cells.

2008

Abstract Pathologic conditions associated with hyperinsulinemia, such as obesity, metabolic syndrome, and diabetes, seem to increase the risk of breast cancer. Here, we studied molecular mechanisms by which insulin activates the expression of leptin, an obesity hormone that has been shown to promote breast cancer progression in an autocrine or paracrine way. Using MDA-MB-231 breast cancer cells, we found that (a) insulin stimulated leptin mRNA and protein expression, which was associated with increased activation of the leptin gene promoter; (b) insulin increased nuclear accumulation of transcription factors hypoxia inducible factor (HIF)-1α and Sp1 and their loading on the leptin promoter;…

LeptinTranscriptional ActivationCancer Researchmedicine.medical_specialtySmall interfering RNAChromatin ImmunoprecipitationSp1 Transcription FactorBlotting WesternFluorescent Antibody TechniqueBreast NeoplasmsEnzyme-Linked Immunosorbent AssayBiologyParacrine signallingPhosphatidylinositol 3-Kinasesbreast cancerInternal medicinemedicineHyperinsulinemiaTumor Cells CulturedHumansHypoglycemic AgentsInsulinRNA MessengerRNA Small InterferingAutocrine signallingLuciferasesPromoter Regions GeneticTranscription factorCell NucleusMitogen-Activated Protein Kinase 1Gene knockdownLeptin receptorMitogen-Activated Protein Kinase 3Reverse Transcriptase Polymerase Chain ReactionLeptinmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaEndocrinologyOncologyCancer researchFemalehormones hormone substitutes and hormone antagonistsCancer research
researchProduct

Watch out for diabetes: Less education but let's get moving, let's eat less!

2016

Lifestyle interventionmedicine.medical_specialtyClinical markers of cardiovascular disease030204 cardiovascular system & hematologyDiabete03 medical and health sciences0302 clinical medicinePatient Education as TopicRisk FactorsDiabetes mellitusLifestyle interventionDiabetes MellitusmedicineInternal MedicineHumansHypoglycemic Agents030212 general & internal medicineExercisebusiness.industrymedicine.diseaseDietCardiovascular DiseasesPharmacogeneticsFamily medicinePhysical therapySedentary BehaviorbusinessDiet Therapy
researchProduct

DIFFERENTIAL SCANNING CALORIMETRY STUDY ON DRUG RELEASE FROM AN INULIN-BASED HYDROGEL AND ITS INTERACTION WITH A BIOMEMBRANE MODEL:pH AND LOADING EFF…

2008

Inulin has been derivatized with methacrylic anhydride (MA) and succinic anhydride (SA) to obtain a methacrylated/succinilated derivative (INU-MA-SA) able to produce a pH sensitive hydrogel after UV irradiation. The hydrogel was characterized and loaded with diflunisal (10.4, 17 and 24%, w/w) chosen as a model drug. The drug release from INU-MA-SA-based hydrogel to a biomembrane model made by unilamellar vesicles of dimyristoylphosphatidyl-choline (DMPC) was investigated at pH 4.0 and 7.4 by differential scanning calorimetry (DSC) that appears to be a suitable technique to follow the transfer kinetics of a drug from a controlled release system to a biomembrane model. The drug release from t…

Magnetic Resonance SpectroscopyINULIN HYDROGELS DRUG RELEASE DIFFERENTIAL SCANNING CALORIMETRYPharmaceutical ScienceDiflunisalMethacrylic anhydrideCentrifugationInsulysinDosage formchemistry.chemical_compoundDifferential scanning calorimetryX-Ray DiffractionSpectroscopy Fourier Transform InfraredmedicineHypoglycemic AgentsChromatography High Pressure LiquidChromatographyCalorimetry Differential ScanningVesicleAnti-Inflammatory Agents Non-Steroidaltechnology industry and agricultureSuccinic anhydrideInulinHydrogelsMembranes ArtificialSuccinatesHydrogen-Ion ConcentrationDiflunisalControlled releaseMolecular WeightchemistryChemical engineeringSolubilitySelf-healing hydrogelsSpectrophotometry UltravioletChromatography Thin LayerDimyristoylphosphatidylcholinemedicine.drug
researchProduct

Nose-to-brain delivery of insulin enhanced by a nanogel carrier.

2018

Recent evidences suggest that insulin delivery to the brain can be an important pharmacological therapy for some neurodegenerative pathologies, including Alzheimer disease (AD). Due to the presence of the Blood Brain Barrier, a suitable carrier and an appropriate route of administration are required to increase the efficacy and safety of the treatment. Here, poly(N-vinyl pyrrolidone)-based nanogels (NG), synthetized by e-beam irradiation, alone and with covalently attached insulin (NG-In) were characterized for biocompatibility and brain delivery features in a mouse model. Preliminarily, the biodistribution of the "empty" nanocarrier after intraperitoneal (i.p.) injection was investigated b…

Male0301 basic medicineIonizing radiationBiodistributionmedicine.medical_treatmentPharmaceutical SciencePharmacologyBrain delivery; Insulin; Intranasal inoculation; Ionizing radiations; Nanogel; Nanogel biocompatibility and clearanceBlood–brain barrierNanogel biocompatibility and clearance03 medical and health sciencesRoute of administrationNanogel0302 clinical medicinemedicineAnimalsHypoglycemic AgentsInsulinProtein kinase BAdministration IntranasalBrain deliveryDrug CarriersChemistryInsulinBrainPovidoneIntranasal inoculationMice Inbred C57BLNasal Mucosa030104 developmental biologymedicine.anatomical_structureAcrylatesNasal administrationSettore CHIM/07 - Fondamenti Chimici Delle TecnologieNanocarriersGels030217 neurology & neurosurgeryNanogel Ionizing radiationNanogel
researchProduct

The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact …

2017

Introduction While metformin (MET) is the most widely prescribed antidiabetic drug worldwide, its beneficial effects in Psammomys obesus (P. obesus), a rodent model that mimics most of the metabolic features of human diabetes, have not been explored thoroughly. Here, we sought to investigate whether MET might improve insulin sensitivity, glucose homeostasis, lipid profile as well as cellular redox and energy balance in P. obesus maintained on a high energy diet (HED). Materials and methods P. obesus gerbils were randomly assigned to receive either a natural diet (ND) consisting of halophytic plants (control group) or a HED (diabetic group) for a period of 24 weeks. MET (50 mg/kg per os) was…

Male0301 basic medicinePhysiologymedicine.medical_treatment[SDV]Life Sciences [q-bio]Body-WeightRespiratory chainlcsh:MedicineMitochondria LiverBiochemistrychemistry.chemical_compoundLiver Parenchymal-CellsEndocrinologyGlucose MetabolismAnimal CellsKetogenesisMedicine and Health SciencesElectrochemistryGlucose homeostasisGut Microbiotalcsh:ScienceEnergy-Producing OrganellesComputingMilieux_MISCELLANEOUS2. Zero hungerMultidisciplinaryOrganic CompoundsMonosaccharidesFatty AcidsChemical ReactionsLipidsMetforminMitochondria3. Good healthChemistryPhysiological ParametersLiverPhysical SciencesCarbohydrate MetabolismCellular Structures and OrganellesCellular TypesAnatomyOxidation-ReductionResearch Articlemedicine.medical_specialtyIsolated Rat HepatocytesEndocrine DisordersCarbohydratesBioenergeticsBiologyCarbohydrate metabolism03 medical and health sciencesInsulin resistanceInternal medicineFood-IntakeDiabetes MellitusmedicineAnimalsHypoglycemic AgentsObesityRespiratory-Chain[ SDV ] Life Sciences [q-bio]Fatty acid metabolismInsulinBody WeightOrganic Chemistrylcsh:RChemical CompoundsGluconeogenesisBiology and Life SciencesCell Biologymedicine.diseaseGlucose-6-Phosphate HydrolysisDisease Models AnimalGlucoseMetabolism030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2GluconeogenesischemistryMetabolic DisordersHepatocyteslcsh:QInsulin ResistanceGerbillinaeGlucose-ProductionFatty-Acid-MetabolismOxidation-Reduction Reactions
researchProduct

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

2017

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothel…

Male0301 basic medicineendocrine system diseasesDiabetic CardiomyopathiesFPS-ZM1 RAGE inhibitorClinical BiochemistryAorta ThoracicRAGE receptor for AGEICAM-1 intercellular adhesion molecule-1ECL enhanced chemiluminescence030204 cardiovascular system & hematologyDPP-4 dipeptidyl peptidase-4medicine.disease_causeTNF-α tumor necrosis factor-αBiochemistryeNOS endothelial •NO synthase (type 3)0302 clinical medicineGlucosidesecSOD extracellular superoxide dismutaseInsulin-Secreting CellsCCL-2 see MCP-1HyperlipidemiaHyperinsulinemiaGTN glyceryl trinitrate (nitroglycerin)IFN-γ interferon-γDHE dihydroethidineEndothelial dysfunctionEndothelial dysfunctionIL-6 interleukin-6lcsh:QH301-705.5HO-1 heme oxygenase-1lcsh:R5-920ICAM-1NG normoglycemiaDiabetesNox catalytic subunit of NADPH oxidaseSGLT2 inhibitorβ-cell contentL-012 8-amino-5-chloro-7-phenylpyrido[34-d]pyridazine-14-(2H3H)dione sodium saltChIP chromatin immunoprecipitationC-Reactive ProteinCRP C-reactive proteinAGE advanced glycation end productsHbA1c glycohemoglobinlcsh:Medicine (General)Research PaperZucker diabetic fatty ratsmedicine.medical_specialtyDMSO dimethylsulfoxideMCP-1 monocyte-chemoattractant-protein-1qRT-PCR quantitative reverse transcription polymerase chain reactionZDF Zucker diabetic fatty (rat)Low-grade inflammation03 medical and health sciencesROS reactive oxygen speciesSodium-Glucose Transporter 2Physiology (medical)Internal medicineDiabetes mellitusPKC protein kinase CEmpagliflozinmedicineAnimalsHypoglycemic AgentsBenzhydryl CompoundsCOX2 cyclooxygenase-2SGLT2i SGLT2 inhibitorSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinACh acetylcholinebusiness.industryOrganic Chemistrynutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseH2K9me2 histone3 lysine9 dimethylationRatsRats ZuckerDHFR dihydrofolate reductaseSGLT2 sodium-glucose co-transporter-2Oxidative StresssGC soluable guanylyl cyclaseGlucose030104 developmental biologyEndocrinologylcsh:Biology (General)ALDH-2 mitochondrial aldehyde dehydrogenaseEndothelium VascularAGE/RAGE signalingHG hyperglycemiabusinessOxidative stressRedox Biology
researchProduct

Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stabl…

2022

BackgroundInformation on the influence of insulin treatment using advanced hybrid closed loop systems (AHCL) on body weight of young patients with type 1 diabetes (T1D) is scarce. The aim of this study was to observe whether there were any changes in body mass index (BMI) of children and adolescents with T1D treated using the Medtronic Minimed 780G AHCL after 1 year of follow up and to analyze potential associations between these changes and the insulin doses.Materials and methodsFor 50 children and adolescents (age 5.4-16.8 years, 24 (48%) boys, T1D for 3.9 ± 2.56 years) using an AHCL system anthropometric and AHCL data were collected prospectively. BMI Z-scores and two-week AHCL records o…

MaleBlood GlucoseAdolescenttype 1 diabetesEndocrinology Diabetes and MetabolismBody WeightGlycemic Controladvanced hybrid closed-loop systemBody Mass IndexBMIDiabetes Mellitus Type 1Insulin Infusion SystemsGlucosechildrenChild Preschooltime in rangetotal daily insulin doseHumansHypoglycemic AgentsInsulinFemalebasal insulinProspective StudiesChildFrontiers in endocrinology
researchProduct

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants

2016

Background One of the global targets for non-communicable diseases is to halt, by 2025, the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to estimate worldwide trends in diabetes, how likely it is for countries to achieve the global target, and how changes in prevalence, together with population growth and ageing, are affecting the number of adults with diabetes. Methods We pooled data from population-based studies that had collected data on diabetes through measurement of its biomarkers. We used a Bayesian hierarchical model to estimate trends in diabetes prevalence-defined as fasting plasma glucose of 7.0 mmol/L or higher, or history of diagnosis w…

MaleBlood GlucoseAdultResearch ReportSettore MED/09 - Medicina Internaglucosa sanguíneaEpidemiologyhumanosEpidemiology; prevention; public health; diabetescoste de las enfermedadesDiabetes epidemiologyGlobal HealthincidenciaWorldwide trendsdistribución por sexosAge DistributionSDG 3 - Good Health and Well-beingCost of Illnessdistribución por edadespreventionpaíses en desarrolloDiabetes MellitusPrevalenceInsulinHumansHypoglycemic AgentsinsulinaAge of OnsetSex DistributionDeveloping CountriesdiabetesVDP::Medical disciplines: 700::Clinical medical disciplines: 750Incidenceprevalenciapublic healthVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750Bayes TheoremadultoHealth Surveysinforme de investigación//purl.org/pe-repo/ocde/ford#3.02.00 [https]hipoglicemiantesencuestas de saludFemalepooled analysisteorema de Bayes
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct